BioSpace News Archive

On February 7, 2024, at this year’s International Stroke Conference, Life Recovery Systems presented the results of its IDE-approved SISCO Study, in which ischemic stroke patients were rapidly cooled with the ThermoSuit System.

Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced that it will release financial results for the full year 2023, after U.S. markets close on Wednesday, March 20, 2024.

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”) today announced that it will report the Company’s fourth quarter 2023 financial results on Tuesday, March 12, 2024, after the close of the U.S. financial markets.

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) today announced financial results for the fourth quarter and year ended December 31, 2023.

Scilex Holding Company announced the closing of its previously announced public offering of 5,882,353 shares of common stock of the Company and accompanying common warrants to purchase up to 5,882,353 shares of common stock, at a combined public offering price of $1.70, less underwriting discounts and commissions.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent and upcoming business highlights.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2023.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2023.

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Thursday, March 14, 2024, at 10:45 a.m. Eastern Time.

Mestag Therapeutics announced the acceptance of a late-breaking abstract titled “Conditionally active, therapeutic lymphotoxin beta receptor agonist bispecific antibodies for induction of tertiary lymphoid structures in the treatment of solid tumors” for presentation at the American Association for Cancer Research meeting taking place April 5-10, 2024 in San Diego, CA.